Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trial
— ADHDOfficial title:
A Phase 2/3 Randomized Double-Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR in Pediatric Subjects With Attention-Deficit/Hyperactivity Disorder
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
Status | Recruiting |
Enrollment | 160 |
Est. completion date | February 1, 2025 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years to 17 Years |
Eligibility | Inclusion Criteria: 1. Male or female, 13-17 years of age at screening. 2. Has a primary diagnosis of ADHD according to the DSM-5 classification, confirmed with MINI using DSM-5 probes. 3. ADHD-related symptoms - ADHD-RS-5 = 26 in screening and baseline. * Baseline score must not change by more than 25% from screening to baseline, except subjects who stop taking ADHD medication after screening may have an increase of more than 25%. 4. Has a minimum score of 4 on the CGI-S at baseline. Exclusion Criteria: 1. PERMP-C score > 200 in Moderate difficulty level in orientation. 2. PERMP-C score > 180 in Easy difficulty level AND < 80 in Moderate difficulty level in orientation. 3. Subject is functioning below an age-appropriate level intellectually, as judged by the Investigator. 4. Lifetime history of severe psychiatric symptoms of major depression requiring hospitalization, bipolar disorder, schizophrenia or schizoaffective disorder, hallucinations, or delusions. Severe comorbid disorders such as PTSD, severe obsessive-compulsive disorder, or other symptomatic presentation that, in the opinion of the examining physician, will contraindicate NRCT-101SR treatment or confound efficacy or safety assessments. Subjects with mild to moderate forms of social phobia or dysthymia, for instance, may be included. 5. History of seizures (other than infantile febrile seizures), any tic disorder (except transient tic disorder and subject has no episodes for at least 1 year), or a current diagnosis of Tourette's Disorder. 6. Recent history (within the past 1 year) of suspected substance abuse or dependence disorder in accordance with DSM-5 criteria. 7. Current abnormal thyroid function as defined as abnormal screening thyroid stimulating hormone. Treatment for at least 3 months with a stable dose of thyroid medication is permitted. 8. History of poor kidney function; corrected estimated glomerular filtration rate (eGFR) < 90 mL/min/m2 9. History of significant gastrointestinal disorders, such as chronic diarrhea, irritable bowel syndrome, ulcerative colitis, Crohn's disease, etc. 10. Female subjects who are pregnant and/or lactating and/or sexually active women of childbearing potential (WOCBP) not agreeing to use birth control methods outlined in inclusion criterion. 11. *A woman is considered fertile following menarche unless permanently sterile; a premenarchal female is not considered a WOBCP). 12. A "yes" answer to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at screening (in the past 12 months). 13. Has history of severe drug allergy or hypersensitivity to the study medication or its excipients. 14. Hypermagnesemia; serum magnesium > 2.5 mg/dL. 15. Hepatic impairment as defined by serum AST, ALT and/or ALP > 1.25 ULN, and/or serum bilirubin > 1.5 ULN. 16. Known history of hepatitis B and/or C.: 17. Is currently participating in another clinical trial or has participated in a clinical trial within 30 days or 5 half-lives of the investigational drug, whichever is longer, prior 18. to the Screening Visit. 19. Currently living in an institutional facility. 20. Severe physical disability not associated with cognitive function that limits ability to complete testing. 21. Known history of symptomatic cardiac disease, advanced atherosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary heart disease, transient ischemic attack or stroke or other serious cardiac problems. 22. Known family history of sudden cardiac death or ventricular arrhythmia. 23. Serious or unstable clinically important systemic illness or disease that, in the judgment of the Investigator, is likely to affect the study assessments, deteriorate, or affect the subject's safety or ability to complete the study, including hepatic (e.g., Child-Pugh grade C), renal, gastroenterological, respiratory, cardiovascular, endocrinologic, immunologic, infectious, or hematologic disorders. 24. Has previously participated in a NRCT-101SR / L-TAMS investigational study. 25. Investigators and their immediate family members are not permitted to participate in the study. 26. Changes in medications or doses of medication as follows: 27. All allowed concomitant medications, supplements, or other substances must be at stable doses for at least 30 days prior to screening and must be kept as stable as medically possible during the trial. For allowed concomitant medications, any dosing change within 30 days of Screening may be allowed if, in the opinion of the Investigator, it will not affect or influence study results. |
Country | Name | City | State |
---|---|---|---|
United States | CenExel ACMR Atlanta Center for Medical Research | Atlanta | Georgia |
United States | Boston Clinical Trials Llc | Boston | Massachusetts |
United States | iRresearch Atlanta | Decatur | Georgia |
United States | Accel Research Sites - Lakeland Clinical Research Unit | Lakeland | Florida |
United States | Center for Psychiatry and Behavioral Medicine | Las Vegas | Nevada |
United States | Accel Research Sites | Maitland | Florida |
United States | Coastal Carolina Research Center - North Charleston | North Charleston | South Carolina |
United States | CenExel iRS - iResearch Savannah | Savannah | Georgia |
Lead Sponsor | Collaborator |
---|---|
Neurocentria, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective performance/Permanent Product Measure of Performance (PERMP-C) Math Tests | PERMP is a skill adjusted math test. PERMP-C is the number of math problems answered correctly in a 10-minute session and typically ranges from 0-400 with higher scores indicating better performance. The mean of the post-dose timepoint scores will be used for evaluation. | over 6 weeks | |
Secondary | Core Symptoms/ADHD Rating Scale (ADHD-RS-5) | The ADHD-RS-5 consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with a total score ranging from 0 to 54. Each item has multiple prompts; the highest score that is generated from each prompt should be used as the score for that item. Evaluations will be based on symptoms over the week prior to the administration. | Over 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02150668 -
Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD
|
N/A | |
Completed |
NCT00631280 -
Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD
|
N/A | |
Recruiting |
NCT05809388 -
Virtual Reality for Parent Training Intervention
|
N/A | |
Completed |
NCT00776009 -
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
|
Phase 4 | |
Recruiting |
NCT00252278 -
Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents
|
Phase 4 | |
Completed |
NCT04016779 -
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
|
Phase 3 | |
Completed |
NCT00307268 -
Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD
|
N/A | |
Completed |
NCT01107496 -
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
|
Phase 1/Phase 2 | |
Completed |
NCT04786990 -
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
|
Phase 4 | |
Completed |
NCT00475735 -
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00711724 -
Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD
|
N/A | |
Completed |
NCT02633527 -
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
|
Phase 2 | |
Withdrawn |
NCT00323700 -
A Naturalistic Prospective Study of Treatment Effectiveness for Attention-Deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
Not yet recruiting |
NCT04532190 -
Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder
|
N/A | |
Withdrawn |
NCT00931398 -
Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate
|
Phase 4 |